LP158087-9
inFLIXimab Ab
Active
Description
Antibodies to infliximab (ATI) are detectable in 20% of pediatric and young adult patients taking infliximab. Patients with ATI have reduced levels of infliximab and a higher risk for surgery in patient with inflammatory bowel disease (IBD). When treatment with infliximab is combined with immunomodulators, the likelihood of developing ATI is reduced when compared to using infliximab alone. PMID: 25569737 Source: Regenstrief LOINC
Basic Part Properties
- Part Display Name
- inFLIXimab Ab
- Part Type
- Component (Describes the core component or analyte measured)
- Created On
- 2012-12-05
- Construct for LOINC Short Name
- inFLIXimab Ab
LOINC Terminology Service (API) using HL7® FHIR® Get Info
Requests to this service require a free LOINC username and password. Below is a sample of the possible capabilities. See the LOINC Terminology Service documentation for more information.
- CodeSystem lookup
- https:
//fhir.loinc.org/CodeSystem/$lookup?system=http: //loinc.org&code=LP158087-9
Language Variants Get Info
| Tag | Language | Translation |
|---|---|---|
| pl-PL | Polish (Poland) | Infliksymab Ab Synonyms: Przeciwciała do Infliksymab |
| fr-CA | French (Canada) | InFLIXimab, Ac |
LOINC Copyright
Copyright © 2024 Regenstrief Institute, Inc. All Rights Reserved. To the extent included herein, the LOINC table and LOINC codes are copyright